Tuesday - July 15, 2025

LOGIN  |  REGISTER
Astria Therapeutics

List of Biotechnology Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 464.77
-7.58 -1.60
697,490
256.80M
US$ 119.350B
US$ 549.21
-21.38 -3.75
852,813
106.15M
US$ 58.300B
US$ 311.12
-4.63 -1.47
911,718
130.39M
US$ 40.570B
US$ 555.96
-5.32 -0.95
346,521
61.20M
US$ 34.020B
US$ 110.65
-0.35 -0.32
770,395
240.40M
US$ 26.600B
US$ 102.87
0.98 0.96
3.56M
189.95M
US$ 19.540B
US$ 24.38
-1.02 -4.02
1.43M
742.67M
US$ 18.110B
US$ 184.71
0.00 0.00
0
97.68M
US$ 18.040B
US$ 36.50
0.25 0.69
1.57M
421.37M
US$ 15.380B
US$ 131.87
0.00 0.00
0
106.24M
US$ 14.010B
US$ 293.23
-4.45 -1.49
202,848
45.11M
US$ 13.230B
US$ 68.25
-1.73 -2.47
1.47M
193.57M
US$ 13.210B
US$ 21.15
-0.31 -1.44
998,358
615.03M
US$ 13.010B
US$ 131.24
-3.89 -2.88
616,654
98.97M
US$ 12.990B
US$ 36.76
0.56 1.55
11,883
349.00M
US$ 12.830B
US$ 31.58
-1.29 -3.92
8.20M
386.74M
US$ 12.210B
US$ 44.06
-1.52 -3.33
1.92M
272.71M
US$ 12.020B
US$ 56.62
-1.61 -2.76
1.23M
191.78M
US$ 10.860B
US$ 174.75
-0.14 -0.08
267,742
60.49M
US$ 10.570B
US$ 46.97
-0.72 -1.51
2.32M
189.88M
US$ 8.920B
US$ 104.78
0.11 0.11
10.24M
84.98M
US$ 8.900B
US$ 129.34
-0.02 -0.02
7.67M
64.58M
US$ 8.350B
US$ 51.45
-1.17 -2.22
1.23M
156.77M
US$ 8.070B
US$ 28.84
1.12 4.04
597,492
277.93M
US$ 8.020B
US$ 11.36
-0.27 -2.32
3.37M
679.81M
US$ 7.720B
US$ 71.41
-1.36 -1.87
974,398
106.04M
US$ 7.570B
US$ 39.59
0.15 0.38
1.95M
184.03M
US$ 7.290B
US$ 37.83
-0.54 -1.41
1.13M
186.27M
US$ 7.050B
US$ 56.60
-1.05 -1.82
916,772
123.22M
US$ 6.970B
US$ 311.14
-8.73 -2.73
244,350
22.20M
US$ 6.910B
US$ 112.30
0.86 0.77
622,917
60.51M
US$ 6.800B
US$ 42.00
-0.55 -1.29
1.67M
159.16M
US$ 6.680B
US$ 37.96
-0.96 -2.47
1.16M
158.76M
US$ 6.030B
US$ 89.34
0.19 0.21
809,429
65.68M
US$ 5.870B
US$ 82.95
-1.64 -1.94
626,111
66.37M
US$ 5.510B
US$ 110.12
-2.21 -1.97
585,801
49.24M
US$ 5.420B
US$ 28.85
-0.84 -2.83
1.33M
164.90M
US$ 4.760B
US$ 31.15
-0.48 -1.52
1.18M
146.29M
US$ 4.560B
US$ 52.73
-3.69 -6.54
3.06M
86.36M
US$ 4.550B
US$ 35.24
-1.14 -3.13
1.11M
129.00M
US$ 4.550B
US$ 38.01
-0.57 -1.48
1.72M
119.43M
US$ 4.540B
US$ 83.58
0.82 0.99
1.64M
52.75M
US$ 4.410B
US$ 17.98
-0.70 -3.75
1.73M
238.73M
US$ 4.290B
US$ 147.73
-2.68 -1.78
280,378
28.90M
US$ 4.270B
US$ 51.76
-0.97 -1.84
954,324
79.72M
US$ 4.130B
US$ 54.99
-0.63 -1.13
485,198
74.48M
US$ 4.100B
US$ 35.19
0.91 2.65
784,716
110.39M
US$ 3.880B
US$ 31.69
-1.88 -5.60
1.66M
120.52M
US$ 3.820B
US$ 68.15
-1.78 -2.55
306,378
55.11M
US$ 3.760B
US$ 38.84
0.25 0.65
921,341
94.95M
US$ 3.690B
US$ 22.01
0.12 0.55
2.22M
167.36M
US$ 3.680B
US$ 46.99
0.00 0.00
0
74.39M
US$ 3.500B
US$ 55.30
0.07 0.13
408,934
61.98M
US$ 3.430B
US$ 44.91
0.01 0.02
1.05M
70.16M
US$ 3.150B
US$ 49.67
-1.19 -2.34
311,525
63.47M
US$ 3.150B
US$ 17.49
-1.10 -5.92
1.82M
171.07M
US$ 2.990B
US$ 31.83
-1.20 -3.63
1.10M
93.68M
US$ 2.980B
US$ 8.42
-0.48 -5.39
1.61M
309.31M
US$ 2.600B
US$ 51.98
-1.30 -2.44
303,621
49.53M
US$ 2.570B
US$ 27.21
-2.03 -6.94
4.15M
94.54M
US$ 2.570B
US$ 20.95
-0.67 -3.10
1.35M
121.98M
US$ 2.560B
US$ 19.35
-0.56 -2.81
1.30M
125.68M
US$ 2.430B
US$ 17.63
-0.98 -5.27
1.25M
138.10M
US$ 2.430B
US$ 2.74
-0.16 -5.52
6.72M
882.62M
US$ 2.420B
US$ 31.48
-1.12 -3.44
444,663
76.73M
US$ 2.420B
US$ 124.30
-2.62 -2.06
176,398
19.29M
US$ 2.400B
US$ 21.03
-1.14 -5.14
395,743
112.27M
US$ 2.360B
US$ 39.19
-0.07 -0.18
634,908
57.92M
US$ 2.270B
US$ 59.98
0.00 0.00
0
34.44M
US$ 2.070B
US$ 63.32
-0.32 -0.50
172,323
32.54M
US$ 2.060B
US$ 14.17
-0.52 -3.54
1.44M
145.28M
US$ 2.060B
US$ 15.08
-0.08 -0.53
842,047
133.62M
US$ 2.010B
US$ 34.84
0.11 0.32
496,219
57.42M
US$ 2.000B
US$ 30.24
-0.27 -0.88
473,513
65.90M
US$ 1.990B
US$ 25.30
-1.35 -5.07
459,517
78.31M
US$ 1.980B
US$ 19.58
-1.59 -7.51
2.98M
100.56M
US$ 1.970B
US$ 56.34
-1.37 -2.37
166,863
34.63M
US$ 1.950B
US$ 25.01
-0.89 -3.44
559,170
76.23M
US$ 1.910B
US$ 21.43
-1.15 -5.09
663,268
87.58M
US$ 1.880B
US$ 37.12
-2.70 -6.78
502,008
50.34M
US$ 1.870B
US$ 15.40
-0.50 -3.14
1.53M
119.20M
US$ 1.840B
US$ 8.72
-0.24 -2.68
2.60M
209.25M
US$ 1.820B
US$ 5.91
-0.33 -5.29
2.87M
307.93M
US$ 1.820B
US$ 18.28
-0.95 -4.94
3.05M
98.28M
US$ 1.800B
US$ 35.15
-0.16 -0.45
174,552
50.23M
US$ 1.770B
US$ 11.09
-0.18 -1.60
1.94M
159.30M
US$ 1.770B
US$ 17.55
-0.35 -1.96
803,380
98.21M
US$ 1.720B
US$ 40.65
-0.88 -2.12
445,627
42.01M
US$ 1.710B
US$ 11.06
-0.49 -4.24
1.50M
151.92M
US$ 1.680B
US$ 37.17
-1.72 -4.42
617,499
44.83M
US$ 1.670B
US$ 11.50
0.41 3.70
3.56M
139.41M
US$ 1.600B
US$ 10.51
-0.61 -5.49
1.18M
145.98M
US$ 1.530B
US$ 22.85
-0.51 -2.18
930,404
66.39M
US$ 1.520B
US$ 25.76
-0.42 -1.60
781,280
59.18M
US$ 1.520B
US$ 17.52
-0.52 -2.88
466,219
86.98M
US$ 1.520B
US$ 23.18
-0.60 -2.52
894,419
63.77M
US$ 1.480B
US$ 16.36
-0.55 -3.25
720,593
88.80M
US$ 1.450B
US$ 13.38
-0.55 -3.95
454,240
105.20M
US$ 1.410B
US$ 10.96
-0.21 -1.88
72,232
127.00M
US$ 1.390B
US$ 13.24
-0.95 -6.69
1.37M
102.11M
US$ 1.350B
US$ 16.31
-0.83 -4.84
474,110
81.59M
US$ 1.330B
US$ 21.65
-1.35 -5.87
663,332
58.99M
US$ 1.280B
US$ 10.44
-0.30 -2.79
1.47M
120.08M
US$ 1.250B
US$ 19.96
0.38 1.94
1.26M
62.78M
US$ 1.250B
US$ 23.00
-0.80 -3.36
149,351
54.49M
US$ 1.250B
US$ 14.51
0.03 0.21
1.19M
85.48M
US$ 1.240B
US$ 5.42
-0.04 -0.73
1.01M
225.16M
US$ 1.220B
US$ 8.99
-0.05 -0.55
1.51M
135.10M
US$ 1.210B
US$ 7.71
-0.13 -1.66
1.17M
155.56M
US$ 1.200B
US$ 11.48
-0.47 -3.93
3.40M
103.58M
US$ 1.190B
US$ 3.95
-0.29 -6.84
6.74M
298.48M
US$ 1.180B
US$ 8.28
-0.63 -7.07
3.15M
141.54M
US$ 1.170B
US$ 3.85
-0.18 -4.47
2.86M
303.93M
US$ 1.170B
US$ 51.50
-3.83 -6.92
678,653
22.12M
US$ 1.140B
US$ 6.88
-0.09 -1.29
3.73M
161.97M
US$ 1.110B
US$ 19.27
-0.30 -1.53
1.00M
57.54M
US$ 1.110B
US$ 4.50
-0.11 -2.39
3.01M
239.26M
US$ 1.080B
US$ 40.00
0.00 0.00
0
27.02M
US$ 1.080B
US$ 51.88
-1.72 -3.21
330,031
20.37M
US$ 1.060B
US$ 3.88
-0.09 -2.27
2.86M
262.64M
US$ 1.020B
US$ 15.99
-0.50 -3.03
170,862
62.03M
US$ 991.860M
US$ 11.02
-0.01 -0.09
3.16M
89.31M
US$ 983.750M
US$ 12.88
-0.47 -3.52
257,790
74.84M
US$ 963.940M
US$ 9.03
-0.62 -6.42
510,542
105.88M
US$ 956.100M
US$ 12.40
1.12 9.93
4.00M
77.09M
US$ 955.760M
US$ 14.62
-0.40 -2.66
212,879
65.18M
US$ 952.930M
US$ 4.18
-0.05 -1.07
4.43M
225.56M
US$ 941.710M
US$ 10.98
0.13 1.20
377,460
85.22M
US$ 935.720M
US$ 12.15
-0.54 -4.26
1.07M
76.45M
US$ 928.870M
US$ 10.87
-0.61 -5.31
1.04M
85.37M
US$ 927.970M
US$ 9.50
0.00 0.00
0
97.47M
US$ 925.960M
US$ 15.31
-1.10 -6.70
547,985
60.35M
US$ 923.960M
US$ 32.75
-0.95 -2.82
458,297
28.15M
US$ 921.910M
US$ 17.87
-0.30 -1.65
1,504
51.03M
US$ 911.650M
US$ 5.29
-0.16 -2.94
1.48M
160.16M
US$ 846.450M
US$ 11.37
0.01 0.09
1.15M
74.43M
US$ 846.270M
US$ 6.85
-0.16 -2.28
1.26M
121.76M
US$ 834.060M
US$ 1.27
-0.07 -5.22
7.16M
636.92M
US$ 808.890M
US$ 12.49
0.00 0.00
0
63.96M
US$ 798.860M
US$ 9.26
-0.59 -5.99
1.20M
86.05M
US$ 796.390M
US$ 21.63
-0.24 -1.10
160,426
36.70M
US$ 793.820M
US$ 26.63
-0.32 -1.19
332,614
29.38M
US$ 782.390M
US$ 14.03
-0.53 -3.64
683,249
54.75M
US$ 767.870M
US$ 15.17
-0.05 -0.33
1.39M
49.95M
US$ 757.740M
US$ 5.30
-0.20 -3.64
845,728
138.24M
US$ 732.670M
US$ 8.40
-0.11 -1.29
966,493
87.01M
US$ 730.880M
US$ 5.96
-0.15 -2.45
208,039
121.55M
US$ 724.440M
US$ 2.14
-0.005 -0.23
4.88M
339.26M
US$ 724.320M
US$ 8.12
-0.29 -3.45
1.98M
89.14M
US$ 723.820M
US$ 10.42
0.07 0.68
440
68.39M
US$ 712.620M
US$ 12.79
0.00 0.00
1.69M
54.68M
US$ 699.360M
US$ 8.57
-0.32 -3.60
319,559
80.37M
US$ 688.770M
US$ 9.84
-0.32 -3.15
479,351
68.81M
US$ 677.090M
US$ 6.57
-0.36 -5.19
1.56M
101.36M
US$ 665.940M
US$ 2.49
-0.16 -6.04
1.68M
266.14M
US$ 662.690M
US$ 2.52
-0.12 -4.55
1.75M
261.53M
US$ 659.060M
US$ 1.95
-0.06 -2.99
36.89M
333.93M
US$ 651.160M
US$ 7.16
-0.45 -5.91
132,762
90.66M
US$ 649.130M
US$ 14.05
-0.44 -3.04
500,004
46.11M
US$ 647.850M
US$ 5.92
-0.17 -2.79
1.33M
108.39M
US$ 641.670M
US$ 11.75
-0.32 -2.65
420,437
54.60M
US$ 641.280M
US$ 19.02
-1.01 -5.04
147,517
32.16M
US$ 611.680M
US$ 8.07
-0.26 -3.12
792,392
75.55M
US$ 609.690M
US$ 3.52
-0.05 -1.26
1.71M
171.44M
US$ 602.610M
US$ 8.46
-0.39 -4.41
376,804
71.17M
US$ 601.740M
US$ 3.13
-0.11 -3.40
551,720
191.53M
US$ 599.490M
US$ 11.13
-0.60 -5.12
127,127
53.79M
US$ 598.680M
US$ 8.57
-0.48 -5.30
720,443
69.81M
US$ 598.270M
US$ 7.83
0.00 0.00
0
76.38M
US$ 598.060M
US$ 14.25
-0.31 -2.13
238,626
40.62M
US$ 578.840M
US$ 11.53
0.06 0.52
111,053
50.00M
US$ 576.500M
US$ 9.19
0.04 0.44
994,071
62.62M
US$ 575.160M
US$ 2.66
-0.06 -2.21
2.70M
212.14M
US$ 564.290M
US$ 8.88
0.05 0.57
721,742
63.47M
US$ 563.610M
US$ 6.37
-0.10 -1.55
800,133
88.33M
US$ 562.220M
US$ 4.28
-0.53 -11.02
4.18M
131.29M
US$ 561.920M
US$ 6.59
0.51 8.39
16,981
85.03M
US$ 560.180M
US$ 10.25
0.06 0.59
346,686
54.54M
US$ 559.040M
US$ 1.85
-0.12 -5.87
1.39M
295.18M
US$ 544.610M
US$ 7.40
-0.47 -5.97
1.90M
72.99M
US$ 540.130M
US$ 10.14
-0.78 -7.15
108,131
53.18M
US$ 538.980M
US$ 8.16
0.00 0.00
0
65.50M
US$ 534.480M
US$ 6.13
-0.22 -3.46
895,531
86.57M
US$ 530.670M
US$ 14.39
-0.24 -1.64
162,038
36.50M
US$ 525.240M
US$ 3.41
0.00 0.00
0
153.89M
US$ 524.760M
US$ 13.83
0.08 0.58
86,831
37.87M
US$ 523.740M
US$ 11.66
-0.35 -2.91
188,507
44.56M
US$ 519.570M
US$ 5.63
0.10 1.81
3.11M
89.00M
US$ 501.070M
US$ 6.72
0.54 8.74
177,058
71.44M
US$ 479.720M
US$ 18.60
-0.36 -1.90
85,855
25.69M
US$ 477.830M
US$ 3.33
-0.13 -3.76
10,014
139.08M
US$ 463.140M
US$ 13.44
-0.43 -3.10
279,899
33.42M
US$ 449.160M
US$ 5.12
-0.20 -3.76
613,462
86.81M
US$ 444.470M
US$ 3.40
-0.29 -7.83
33.78M
129.54M
US$ 440.570M
US$ 7.45
-0.42 -5.34
237,859
59.01M
US$ 439.620M
US$ 9.42
-0.52 -5.23
1.18M
46.34M
US$ 436.520M
US$ 17.95
0.15 0.84
2,339
24.03M
US$ 431.390M
US$ 4.71
-0.30 -5.99
1.00M
90.54M
US$ 426.440M
US$ 7.84
-0.06 -0.76
339,132
53.98M
US$ 423.200M
US$ 5.41
-0.06 -1.10
512,923
77.52M
US$ 419.000M
US$ 8.29
-0.41 -4.71
353,307
50.39M
US$ 417.730M
US$ 1.15
-0.03 -2.54
3.28M
363.18M
US$ 417.660M
US$ 23.80
-0.68 -2.78
1.16M
17.30M
US$ 411.740M
US$ 6.56
-0.19 -2.81
116,310
62.00M
US$ 406.720M
US$ 1.41
-0.05 -3.42
406,597
283.29M
US$ 399.440M
US$ 4.02
-0.01 -0.25
1.15M
99.33M
US$ 399.310M
US$ 2.31
-0.21 -8.17
545,348
172.84M
US$ 398.400M
US$ 10.31
-0.04 -0.39
1.02M
38.27M
US$ 394.560M
US$ 14.43
-0.11 -0.76
753,115
26.82M
US$ 387.010M
US$ 0.26
-0.001 -0.38
3.66M
1.46B
US$ 385.440M
US$ 3.65
0.00 0.00
0
104.39M
US$ 381.020M
US$ 2.40
0.02 0.84
639,707
157.54M
US$ 378.100M
US$ 7.15
0.00 0.00
0
52.76M
US$ 377.230M
US$ 8.07
0.00 0.00
346,426
46.67M
US$ 376.630M
US$ 2.59
-0.08 -3.00
2.53M
143.98M
US$ 372.910M
US$ 7.68
-0.40 -4.95
157,920
47.76M
US$ 366.800M
US$ 3.26
-0.09 -2.69
1.50M
112.26M
US$ 365.970M
US$ 5.87
-0.92 -13.55
114,989
62.15M
US$ 365.010M
US$ 13.15
-0.16 -1.20
511,364
27.12M
US$ 356.630M
US$ 2.28
-0.19 -7.69
2.76M
155.12M
US$ 353.670M
US$ 13.53
0.46 3.52
55,752
25.95M
US$ 350.970M
US$ 4.18
-0.08 -1.88
2.77M
81.11M
US$ 339.040M
US$ 18.91
-0.45 -2.32
127,067
17.87M
US$ 337.920M
US$ 3.50
-0.10 -2.78
392,800
96.00M
US$ 336.000M
US$ 6.21
-0.22 -3.42
444,605
53.83M
US$ 334.280M
US$ 2.61
-0.05 -1.88
3.32M
127.56M
US$ 332.930M
US$ 22.96
-0.08 -0.35
108,149
14.48M
US$ 332.460M
US$ 1.45
-0.08 -5.23
2.04M
227.30M
US$ 329.580M
US$ 7.18
-0.21 -2.84
2.51M
45.71M
US$ 327.970M
US$ 15.78
-0.32 -1.99
95,543
20.71M
US$ 326.800M
US$ 44.40
1.62 3.79
1.35M
7.36M
US$ 326.780M
US$ 12.44
-0.81 -6.11
66,108
26.25M
US$ 326.550M
US$ 1.11
0.00 0.00
3.48M
292.03M
US$ 324.150M
US$ 5.80
-0.08 -1.36
171,562
55.74M
US$ 323.290M
US$ 5.23
-0.03 -0.57
458,682
61.51M
US$ 321.700M
US$ 4.17
-0.18 -4.14
431,602
77.11M
US$ 321.550M
US$ 4.59
-0.24 -4.97
340,410
68.42M
US$ 314.050M
US$ 26.23
-1.53 -5.51
63,088
11.97M
US$ 313.970M
US$ 6.25
-0.18 -2.80
1.57M
50.10M
US$ 313.120M
US$ 2.04
-0.08 -3.77
1.36M
152.56M
US$ 311.220M
US$ 21.52
-0.75 -3.37
131,777
14.26M
US$ 306.800M
US$ 5.99
0.07 1.18
581,860
51.16M
US$ 306.450M
US$ 3.57
-0.19 -5.05
322,805
85.58M
US$ 305.520M
US$ 2.82
-0.24 -7.70
2.00M
107.74M
US$ 303.290M
US$ 9.51
0.04 0.42
570,063
30.67M
US$ 291.520M
US$ 4.85
-0.16 -3.17
969,644
59.90M
US$ 290.570M
C$ 4.00
-0.13 -3.15
502,376
71.94M
C$ 287.760M
US$ 4.77
-0.21 -4.12
408,195
58.93M
US$ 280.800M
US$ 2.24
-0.15 -6.23
6.84M
124.96M
US$ 280.040M
US$ 10.17
-0.06 -0.59
20,877
27.35M
US$ 278.010M
US$ 2.50
-0.11 -4.21
676,845
109.71M
US$ 274.270M
US$ 4.12
-0.01 -0.24
836,294
66.53M
US$ 274.100M
US$ 1.71
-0.01 -0.58
2.65M
159.00M
US$ 271.890M
US$ 1.24
-0.05 -3.88
1.86M
218.73M
US$ 271.230M
US$ 4.89
-0.07 -1.41
1.46M
54.95M
US$ 268.710M
US$ 3.15
-0.08 -2.48
121,570
84.82M
US$ 267.180M
C$ 7.34
-0.19 -2.52
33,820
35.85M
C$ 263.140M
US$ 1.35
-0.11 -7.53
935,611
191.16M
US$ 258.070M
US$ 5.00
0.00 0.00
0
51.59M
US$ 257.950M
US$ 4.00
0.00 0.00
0
64.24M
US$ 256.960M
US$ 4.81
-0.36 -6.96
1.35M
52.76M
US$ 253.780M
US$ 2.37
-0.11 -4.44
222,051
105.34M
US$ 249.660M
US$ 5.26
0.11 2.14
11,783
47.40M
US$ 249.470M
US$ 39.76
-3.97 -9.08
85,357
6.12M
US$ 243.330M
US$ 6.36
-0.44 -6.47
97,793
37.95M
US$ 241.360M
US$ 8.71
-0.08 -0.91
53,281
27.62M
US$ 240.570M
US$ 2.87
0.02 0.70
1.54M
83.71M
US$ 240.250M
US$ 1.96
-0.10 -4.63
551,758
122.34M
US$ 239.170M
US$ 1.63
-0.05 -2.98
86,566
145.56M
US$ 237.260M
US$ 1.03
-0.05 -4.21
1.28M
228.36M
US$ 234.070M
US$ 1.45
0.18 13.78
1.96M
161.75M
US$ 233.730M
US$ 2.81
-0.26 -8.47
998,756
82.84M
US$ 232.780M
US$ 4.39
-0.09 -1.90
175,970
52.79M
US$ 231.480M
US$ 3.85
-0.06 -1.53
683,050
59.88M
US$ 230.540M
US$ 2.27
0.00 0.00
0
100.33M
US$ 227.750M
US$ 1.13
-0.05 -4.24
1.80M
198.20M
US$ 223.970M
US$ 4.14
-0.30 -6.66
237,039
53.98M
US$ 223.210M
US$ 3.93
-0.08 -1.88
129,220
56.77M
US$ 222.820M
US$ 20.01
-0.55 -2.68
60,462
10.81M
US$ 216.310M
US$ 3.03
0.22 7.65
2.34M
71.16M
US$ 215.260M
US$ 4.61
0.02 0.33
2.42M
46.52M
US$ 214.220M
US$ 3.61
-0.32 -8.14
947,485
58.59M
US$ 211.510M
US$ 2.05
-0.03 -1.44
126,268
100.60M
US$ 206.230M
US$ 4.26
0.00 0.00
0
48.13M
US$ 205.030M
US$ 3.16
-0.29 -8.41
856,181
64.03M
US$ 202.330M
US$ 4.16
-0.22 -5.02
250,588
46.32M
US$ 192.690M
US$ 4.24
-0.12 -2.75
112,201
45.30M
US$ 192.070M
US$ 1.90
-0.08 -4.04
10.42M
99.78M
US$ 189.580M
US$ 3.79
0.00 0.00
686
50.00M
US$ 189.500M
US$ 4.30
0.29 7.23
288,376
42.88M
US$ 184.380M
US$ 10.83
2.13 24.48
730,340
16.54M
US$ 179.130M
US$ 2.80
-0.05 -1.75
424,811
63.29M
US$ 177.210M
US$ 8.28
0.06 0.73
112,668
20.89M
US$ 172.970M
US$ 3.48
0.02 0.43
399,104
49.64M
US$ 172.500M
US$ 24.36
-1.29 -5.03
35,495
7.08M
US$ 172.470M
US$ 1.47
-0.01 -0.68
101,282
116.85M
US$ 171.770M
US$ 2.10
-0.04 -1.87
110,955
81.66M
US$ 171.490M
US$ 7.43
-0.02 -0.27
401,312
23.02M
US$ 171.080M
US$ 3.09
-0.35 -10.06
742,625
55.34M
US$ 170.720M
US$ 6.22
-0.61 -8.93
1.26M
27.42M
US$ 170.550M
US$ 2.95
0.01 0.34
1.15M
56.86M
US$ 167.740M
US$ 10.35
-0.18 -1.71
31,582
16.02M
US$ 165.810M
US$ 3.83
-0.56 -12.76
448,140
43.22M
US$ 165.530M
US$ 1.52
-0.06 -3.80
561,780
108.28M
US$ 164.590M
US$ 1.77
0.07 4.12
3,287
92.16M
US$ 163.120M
US$ 4.51
-0.13 -2.70
135,588
35.85M
US$ 161.500M
US$ 24.07
-0.42 -1.71
195,897
6.56M
US$ 157.900M
US$ 11.00
-0.53 -4.60
101,985
14.34M
US$ 157.740M
US$ 1.55
-0.13 -7.74
292,761
99.99M
US$ 154.980M
US$ 2.13
-0.02 -0.93
339,483
72.33M
US$ 154.060M
US$ 4.18
0.01 0.24
995,023
35.99M
US$ 150.440M
US$ 1.61
-0.09 -5.29
1.86M
93.00M
US$ 149.730M
US$ 1.58
-0.01 -0.63
152,850
93.51M
US$ 147.750M
US$ 9.19
0.19 2.11
18,919
16.00M
US$ 147.040M
US$ 1.63
-0.06 -3.55
834,956
89.94M
US$ 146.600M
US$ 18.64
-0.20 -1.06
36,552
7.64M
US$ 142.410M
US$ 6.59
-0.36 -5.18
257,933
21.38M
US$ 140.890M
US$ 2.49
-0.15 -5.68
973,115
55.91M
US$ 139.220M
US$ 10.08
-0.73 -6.75
162,950
13.37M
US$ 134.770M
US$ 9.10
-0.57 -5.89
35,974
14.81M
US$ 134.770M
US$ 1.80
-0.14 -7.22
153,839
74.34M
US$ 133.810M
US$ 4.76
-0.14 -2.86
27,662
28.05M
US$ 133.520M
US$ 3.57
0.02 0.56
627
36.87M
US$ 131.630M
US$ 2.64
-0.11 -4.00
2.54M
49.69M
US$ 131.180M
US$ 1.13
-0.02 -1.74
1.47M
114.63M
US$ 129.530M
US$ 1.82
-0.07 -3.70
524,264
70.96M
US$ 129.150M
US$ 14.67
-0.18 -1.21
165,028
8.73M
US$ 128.070M
US$ 12.64
-0.33 -2.54
122,588
9.39M
US$ 118.690M
US$ 0.92
-0.02 -2.31
423,538
129.17M
US$ 118.190M
US$ 3.06
-0.10 -3.16
154,061
38.58M
US$ 118.050M
US$ 6.01
-0.19 -3.06
42,719
19.62M
US$ 117.860M
US$ 0.48
-0.02 -4.00
8.98M
245.40M
US$ 117.790M
US$ 3.75
-0.18 -4.58
683,649
30.98M
US$ 116.180M
US$ 2.11
-0.02 -0.94
165,219
54.80M
US$ 115.630M
US$ 3.06
-0.32 -9.47
268,670
37.74M
US$ 115.480M
US$ 9.45
-0.39 -3.96
45,522
12.21M
US$ 115.380M
C$ 1.74
0.01 0.58
27,600
65.91M
C$ 114.680M
US$ 0.69
-0.02 -2.73
2.36M
162.67M
US$ 112.570M
US$ 1.70
0.00 0.00
544,295
65.88M
US$ 112.000M
US$ 2.91
-0.12 -3.96
120,277
38.31M
US$ 111.480M
US$ 27.86
-12.75 -31.40
1.46M
3.99M
US$ 111.160M
US$ 1.39
-0.04 -2.46
1.64M
79.61M
US$ 110.260M
US$ 1.12
-0.08 -6.58
644,906
96.60M
US$ 108.290M
US$ 7.77
-0.20 -2.51
8,832
13.83M
US$ 107.460M
US$ 2.13
-0.05 -2.07
64,237
50.10M
US$ 106.460M
US$ 2.78
0.20 7.75
78,875
37.42M
US$ 104.030M
US$ 1.71
0.00 0.00
0
60.18M
US$ 102.910M
US$ 3.19
-0.02 -0.47
165,677
32.21M
US$ 102.590M
US$ 6.09
-0.07 -1.14
100,429
16.73M
US$ 101.840M
US$ 1.78
-0.15 -7.77
1.06M
57.02M
US$ 101.500M
US$ 2.05
-0.11 -5.09
576,205
48.31M
US$ 99.040M
US$ 8.06
-0.30 -3.59
139,889
12.24M
US$ 98.650M
US$ 0.85
-0.10 -10.60
2.73M
115.93M
US$ 98.420M
US$ 1.35
-0.01 -0.74
964,837
71.95M
US$ 97.130M
US$ 2.27
-0.06 -2.37
826,259
42.85M
US$ 97.060M
US$ 1.49
-0.09 -5.70
412,602
63.09M
US$ 94.000M
US$ 2.31
0.02 0.87
21,418
40.32M
US$ 93.140M
C$ 0.56
-0.03 -5.08
498,320
165.88M
C$ 92.890M
US$ 1.76
-0.17 -8.59
523,632
52.31M
US$ 91.800M
US$ 0.72
-0.05 -6.94
157,746
126.15M
US$ 90.830M
US$ 1.74
-0.05 -2.53
157,456
52.14M
US$ 90.460M
US$ 8.09
0.05 0.62
16,754
11.13M
US$ 89.990M
US$ 1.91
0.08 4.32
907,225
47.11M
US$ 89.930M
US$ 0.39
-0.03 -7.14
4.13M
228.22M
US$ 89.010M
C$ 0.77
0.17 28.33
1.25M
112.54M
C$ 86.660M
US$ 2.39
0.10 4.19
68,686
36.19M
US$ 86.350M
US$ 1.89
0.09 5.00
157,584
45.45M
US$ 85.900M
US$ 1.40
-0.06 -3.79
750,419
61.39M
US$ 85.640M
US$ 2.09
-0.04 -1.88
83,180
40.85M
US$ 85.380M
US$ 2.76
-0.14 -4.67
25,644
30.49M
US$ 84.000M
US$ 1.82
-0.16 -8.08
3.99M
45.77M
US$ 83.300M
US$ 1.87
0.01 0.54
1.42M
44.39M
US$ 83.010M
US$ 0.68
-0.04 -6.15
792,608
119.96M
US$ 81.810M
US$ 1.46
0.05 3.55
223,322
55.56M
US$ 81.120M
US$ 1.30
-0.005 -0.38
225,393
61.88M
US$ 80.130M
US$ 0.83
-0.007 -0.83
1.25M
95.82M
US$ 79.820M
US$ 1.49
0.11 7.97
3.67M
53.46M
US$ 79.660M
US$ 1.31
-0.18 -12.08
4.19M
60.57M
US$ 79.350M
US$ 2.08
-0.18 -7.78
678,194
37.38M
US$ 77.560M
US$ 2.68
0.00 0.00
0
28.91M
US$ 77.480M
US$ 3.00
0.00 0.00
0
24.68M
US$ 74.040M
US$ 0.80
-0.02 -2.09
324,968
92.49M
US$ 73.810M
C$ 2.68
-0.07 -2.55
17,700
27.42M
C$ 73.490M
US$ 1.50
-0.08 -4.78
269,396
48.98M
US$ 73.230M
US$ 3.80
0.07 1.74
114,108
19.14M
US$ 72.640M
US$ 0.27
-0.008 -2.85
416,278
265.05M
US$ 72.360M
US$ 1.17
-0.03 -2.10
377,431
61.95M
US$ 72.170M
US$ 8.42
-0.20 -2.32
7,301
8.56M
US$ 72.030M
C$ 0.97
0.00 0.00
0
74.16M
C$ 71.940M
US$ 3.81
0.03 0.71
2,607
18.29M
US$ 69.630M
US$ 2.58
-0.10 -3.73
127,225
26.97M
US$ 69.580M
US$ 1.32
-0.03 -2.22
492,643
51.95M
US$ 68.570M
US$ 1.42
0.05 3.65
811,442
48.26M
US$ 68.530M
C$ 0.82
-0.01 -1.20
8,546
83.38M
C$ 68.370M
US$ 5.69
0.00 0.00
0
11.82M
US$ 67.260M
US$ 2.30
-0.09 -3.57
272,951
29.16M
US$ 66.920M
US$ 1.31
-0.05 -3.68
2.68M
50.96M
US$ 66.760M
US$ 4.50
-0.14 -2.92
61,329
14.80M
US$ 66.530M
US$ 19.44
-1.58 -7.52
102,978
3.42M
US$ 66.480M
US$ 0.74
0.0028 0.38
264,221
89.70M
US$ 65.930M
US$ 1.40
0.00 0.00
5,000
46.82M
US$ 65.550M
US$ 1.57
-0.04 -2.48
49,827
41.08M
US$ 64.500M
US$ 0.83
-0.002 -0.24
75,035
77.71M
US$ 64.270M
US$ 0.28
0.0021 0.75
1.03M
225.72M
US$ 63.880M
US$ 0.75
-0.01 -1.53
465,207
84.46M
US$ 63.510M
US$ 0.76
-0.02 -2.13
203,712
82.71M
US$ 63.030M
US$ 7.22
0.11 1.55
116,233
8.70M
US$ 62.810M
US$ 1.43
-0.14 -8.85
221,020
42.89M
US$ 61.380M
US$ 3.11
-0.10 -3.12
336,084
19.50M
US$ 60.640M
US$ 3.57
0.06 1.71
400,258
16.98M
US$ 60.620M
US$ 1.23
-0.04 -3.15
61,528
49.05M
US$ 60.330M
US$ 0.42
0.002 0.48
3.71M
141.58M
US$ 59.890M
US$ 4.63
-0.25 -5.12
641,894
12.77M
US$ 59.130M
US$ 1.31
0.02 1.55
397,864
44.87M
US$ 58.780M
US$ 2.43
0.19 8.48
7.65M
23.95M
US$ 58.200M
C$ 0.74
-0.01 -1.33
19,950
78.01M
C$ 57.730M
US$ 1.94
-0.02 -1.02
249,761
29.57M
US$ 57.370M
US$ 6.34
-0.14 -2.16
20,813
9.04M
US$ 57.280M
US$ 0.84
-0.05 -5.83
375,506
67.75M
US$ 56.910M
C$ 0.74
0.00 0.00
0
76.57M
C$ 56.660M
US$ 2.07
-0.05 -2.36
1.40M
27.24M
US$ 56.390M
US$ 9.27
-0.03 -0.32
82,858
5.96M
US$ 55.250M
US$ 2.63
-0.10 -3.66
116,040
20.89M
US$ 54.940M
US$ 5.37
0.21 4.08
65,611
9.97M
US$ 53.490M
US$ 1.16
-0.08 -6.10
377,606
45.71M
US$ 52.800M
C$ 0.08
0.00 0.00
0
701.73M
C$ 52.630M
US$ 1.71
-0.07 -3.93
541,089
30.77M
US$ 52.620M
US$ 2.70
-0.17 -5.77
217,333
19.49M
US$ 52.530M
US$ 0.87
0.00 0.00
0
60.34M
US$ 52.500M
US$ 4.80
-0.10 -2.04
32,770
10.83M
US$ 51.980M
US$ 2.13
-0.06 -2.52
173,015
24.36M
US$ 51.760M
US$ 1.70
-0.13 -7.10
391,477
29.95M
US$ 50.920M
C$ 0.16
-0.005 -3.12
324,700
328.48M
C$ 50.910M
US$ 0.58
-0.02 -2.98
1.05M
86.16M
US$ 50.150M
US$ 3.31
-0.16 -4.61
597,300
15.02M
US$ 49.720M
US$ 4.48
-0.16 -3.45
201,852
11.09M
US$ 49.680M
US$ 1.89
-0.08 -4.06
335,071
26.08M
US$ 49.290M
US$ 9.81
0.00 0.00
0
5.02M
US$ 49.250M
US$ 4.97
0.00 0.00
0
9.72M
US$ 48.310M
US$ 1.32
-0.08 -5.71
228,822
36.57M
US$ 48.270M
US$ 1.59
0.03 1.92
423,865
30.22M
US$ 48.050M
US$ 13.50
0.00 0.00
0
3.55M
US$ 47.920M
US$ 1.98
-0.02 -1.00
210,230
23.99M
US$ 47.500M
US$ 1.52
-0.05 -3.18
213,745
31.20M
US$ 47.420M
US$ 1.51
0.00 0.00
0
31.24M
US$ 47.170M
US$ 1.35
-0.01 -0.74
859,338
34.80M
US$ 46.980M
US$ 1.14
0.00 0.00
0
41.10M
US$ 46.850M
US$ 2.73
0.00 0.00
0
16.84M
US$ 45.970M
US$ 8.50
-0.19 -2.19
52,684
5.31M
US$ 45.140M
US$ 16.88
0.17 1.02
1,704
2.62M
US$ 44.230M
US$ 3.19
-0.12 -3.63
91,217
13.83M
US$ 44.120M
US$ 6.87
-0.34 -4.72
546,871
6.32M
US$ 43.420M
C$ 0.49
-0.01 -2.00
100,459
88.52M
C$ 43.370M
US$ 2.47
-0.07 -2.76
80,153
17.27M
US$ 42.660M
US$ 1.27
-0.03 -1.94
120,999
32.72M
US$ 41.390M
US$ 1.02
0.00 0.00
25,414
40.34M
US$ 41.150M
C$ 0.29
-0.005 -1.69
154,873
141.03M
C$ 40.900M
US$ 0.33
-0.02 -4.96
1.41M
124.63M
US$ 40.630M
US$ 3.76
-0.23 -5.76
679,975
10.78M
US$ 40.530M
US$ 1.28
-0.06 -4.14
454,168
31.36M
US$ 39.980M
US$ 5.02
-0.07 -1.38
92,568
7.87M
US$ 39.470M
US$ 0.98
-0.02 -2.00
1.49M
40.00M
US$ 39.200M
US$ 0.78
-0.04 -4.39
110,799
47.90M
US$ 37.550M
US$ 4.34
0.00 0.00
0
8.65M
US$ 37.540M
US$ 1.41
-0.07 -4.73
47,569
26.31M
US$ 37.100M
C$ 0.80
0.00 0.00
25,100
46.31M
C$ 37.050M
US$ 0.71
-0.02 -3.18
137,544
51.78M
US$ 36.920M
US$ 4.24
-0.53 -11.11
250,565
8.64M
US$ 36.630M
US$ 0.59
-0.02 -2.48
4.03M
61.99M
US$ 36.570M
C$ 0.66
0.00 0.00
32,000
54.73M
C$ 36.120M
US$ 3.53
0.14 4.13
312,590
10.19M
US$ 35.970M
US$ 2.85
0.00 0.00
0
12.58M
US$ 35.850M
US$ 0.81
-0.009 -1.10
341,843
43.61M
US$ 35.320M
US$ 5.48
-0.23 -4.04
82,469
6.45M
US$ 35.310M
US$ 1.09
-0.01 -0.91
18,752
32.18M
US$ 35.080M
US$ 1.33
0.00 0.00
0
26.20M
US$ 34.850M
US$ 1.14
-0.04 -2.99
485,392
29.76M
US$ 33.780M
US$ 4.61
0.03 0.66
39,749
7.31M
US$ 33.700M
US$ 3.70
-0.03 -0.80
85,458
8.98M
US$ 33.230M
C$ 0.43
0.00 0.00
0
74.76M
C$ 32.150M
US$ 2.49
-0.01 -0.40
67,639
12.82M
US$ 31.920M
US$ 1.40
-0.10 -6.67
16,566
22.15M
US$ 31.010M
US$ 9.74
0.09 0.93
4.55M
3.17M
US$ 30.860M
US$ 0.85
-0.03 -3.84
75,067
36.17M
US$ 30.780M
US$ 0.55
0.00 0.00
0
55.22M
US$ 30.370M
US$ 0.33
0.00 0.00
0
90.38M
US$ 29.740M
US$ 7.32
-0.37 -4.81
20,206
4.04M
US$ 29.570M
US$ 0.98
0.01 1.03
19,669
30.09M
US$ 29.490M
US$ 1.23
-0.05 -3.91
66,421
23.85M
US$ 29.340M
US$ 2.05
-0.27 -11.64
56,448
13.97M
US$ 28.640M
US$ 0.43
-0.01 -3.18
1.83M
67.04M
US$ 28.560M
US$ 0.34
-0.03 -7.02
4.84M
83.89M
US$ 28.440M
US$ 1.41
-0.06 -4.08
151,674
20.16M
US$ 28.430M
US$ 0.70
0.06 8.59
942,156
39.24M
US$ 27.270M
US$ 0.39
-0.04 -9.39
4.43M
68.00M
US$ 26.450M
US$ 0.37
-0.03 -7.28
1.12M
71.11M
US$ 26.170M
C$ 0.20
0.00 0.00
0
129.54M
C$ 25.910M
US$ 1.12
-0.03 -2.61
261,935
22.39M
US$ 25.080M
US$ 2.82
-0.27 -8.74
4.76M
8.85M
US$ 24.960M
US$ 0.46
-0.0038 -0.82
524,350
53.44M
US$ 24.690M
US$ 6.68
-0.23 -3.33
69,107
3.68M
US$ 24.560M
US$ 5.90
-0.01 -0.17
4,453
4.15M
US$ 24.460M
US$ 5.32
0.00 0.00
0
4.57M
US$ 24.310M
US$ 12.13
-0.37 -2.96
29,427
1.97M
US$ 23.900M
US$ 1.47
-0.13 -8.12
432,157
16.07M
US$ 23.620M
US$ 2.03
-0.18 -8.14
40,180
11.54M
US$ 23.430M
US$ 2.72
0.08 3.03
492,952
8.60M
US$ 23.390M
US$ 0.39
-0.0058 -1.46
568,087
58.42M
US$ 22.840M
US$ 6.16
-0.39 -5.95
13,445
3.65M
US$ 22.480M
US$ 0.38
-0.001 -0.26
488,364
59.25M
US$ 22.460M
C$ 0.15
0.00 0.00
0
148.22M
C$ 22.230M
US$ 1.84
-0.04 -2.13
70,931
12.00M
US$ 22.080M
US$ 1.73
0.07 4.22
376,755
12.72M
US$ 22.010M
US$ 1.14
-0.03 -2.56
334,118
19.16M
US$ 21.840M
US$ 1.28
-0.05 -3.76
253,651
16.66M
US$ 21.320M
C$ 0.08
0.02 36.36
3.64M
284.26M
C$ 21.320M
US$ 7.62
-0.56 -6.85
1,268
2.79M
US$ 21.250M
US$ 0.62
-0.0065 -1.04
143,905
33.19M
US$ 20.610M
US$ 1.33
-0.11 -7.64
29,751
15.49M
US$ 20.600M
US$ 3.07
0.13 4.42
136,635
6.66M
US$ 20.450M
US$ 2.36
0.00 0.00
0
8.62M
US$ 20.340M
C$ 0.14
0.005 3.70
15,950
145.31M
C$ 20.340M
US$ 1.06
-0.05 -4.50
248,875
19.08M
US$ 20.220M
US$ 0.27
-0.04 -12.90
160,147
74.75M
US$ 20.180M
US$ 12.65
9.34 282.18
102.62M
1.58M
US$ 19.990M
US$ 1.47
0.03 2.08
267,064
13.53M
US$ 19.890M
US$ 0.58
-0.004 -0.69
4.94M
34.52M
US$ 19.850M
US$ 0.05
0.0061 13.29
145.31M
381.62M
US$ 19.840M
US$ 2.17
0.02 0.93
65,158
8.98M
US$ 19.490M
US$ 4.55
-0.18 -3.81
144,789
4.25M
US$ 19.340M
US$ 0.05
0.00 0.00
0
408.29M
US$ 19.190M
US$ 1.05
-0.02 -1.87
140,401
18.06M
US$ 18.960M
US$ 3.55
-0.08 -2.20
310,334
5.14M
US$ 18.250M
US$ 13.60
0.00 0.00
0
1.32M
US$ 17.950M
US$ 1.57
-0.01 -0.63
55,238
11.31M
US$ 17.760M
US$ 1.34
-0.09 -6.29
275,329
13.21M
US$ 17.700M
US$ 1.63
-0.05 -2.69
1.94M
10.83M
US$ 17.600M
US$ 0.70
0.0099 1.45
2.16M
25.16M
US$ 17.490M
US$ 1.70
-0.07 -3.73
37,741
10.17M
US$ 17.330M
C$ 0.03
0.00 0.00
0
570.65M
C$ 17.120M
US$ 0.41
-0.04 -9.49
676,297
41.79M
US$ 17.050M
US$ 0.41
-0.01 -3.33
2.54M
41.61M
US$ 16.890M
US$ 4.52
-0.18 -3.83
39,073
3.72M
US$ 16.810M
US$ 0.42
-0.28 -39.43
11.24M
39.24M
US$ 16.600M
US$ 0.32
-0.01 -4.25
5.58M
51.00M
US$ 16.420M
US$ 2.57
-0.10 -3.82
78,108
6.32M
US$ 16.230M
US$ 1.38
0.14 11.29
747,042
11.70M
US$ 16.150M
US$ 3.00
-0.20 -6.25
34,972
5.35M
US$ 16.050M
US$ 0.81
-0.02 -2.41
141,367
19.56M
US$ 15.920M
C$ 0.06
0.00 0.00
0
258.84M
C$ 15.530M
US$ 2.18
-0.02 -0.91
122,992
7.02M
US$ 15.300M
US$ 1.01
-0.04 -3.81
381,510
15.08M
US$ 15.230M
C$ 0.72
0.02 2.86
22,628
21.15M
C$ 15.230M
US$ 0.63
-0.0011 -0.17
3.70M
24.10M
US$ 15.160M
US$ 0.39
-0.02 -4.30
72,133
39.04M
US$ 15.030M
US$ 1.17
0.48 70.78
240.38M
12.85M
US$ 15.030M
US$ 10.90
-0.54 -4.72
49,978
1.36M
US$ 14.820M
US$ 1.96
-0.001 -0.05
90,585
7.36M
US$ 14.420M
US$ 0.44
-0.08 -16.15
2.80M
32.69M
US$ 14.250M
US$ 7.57
-0.13 -1.69
32,735
1.88M
US$ 14.230M
US$ 0.34
0.0049 1.48
428,070
41.44M
US$ 13.880M
US$ 4.78
-0.20 -4.02
71,754
2.86M
US$ 13.670M
C$ 0.09
-0.01 -10.00
1,400
151.84M
C$ 13.670M
US$ 0.38
0.01 3.93
1.12M
35.72M
US$ 13.610M
US$ 8.48
-0.23 -2.64
45,426
1.60M
US$ 13.570M
US$ 1.05
0.02 1.46
61,844
12.88M
US$ 13.460M
US$ 2.90
0.15 5.38
253,654
4.60M
US$ 13.330M
US$ 5.76
-0.29 -4.79
34,431
2.28M
US$ 13.130M
US$ 6.99
0.37 5.59
45,682
1.86M
US$ 13.000M
US$ 1.81
0.03 1.91
12,116
6.99M
US$ 12.680M
US$ 2.29
-0.04 -1.72
79,689
5.45M
US$ 12.480M
US$ 0.22
0.00 0.00
0
55.66M
US$ 11.990M
US$ 2.85
-0.03 -1.04
83,848
4.19M
US$ 11.940M
US$ 1.21
0.005 0.42
197,296
9.84M
US$ 11.860M
US$ 0.72
-0.05 -5.88
845,529
16.22M
US$ 11.680M
US$ 3.24
-0.06 -1.82
16,523
3.56M
US$ 11.530M
US$ 2.40
-0.01 -0.41
59,979
4.80M
US$ 11.520M
US$ 1.90
-0.12 -5.94
2.46M
6.06M
US$ 11.510M
US$ 1.17
-0.03 -2.50
149,380
9.80M
US$ 11.470M
US$ 1.53
-0.08 -4.69
167,399
7.50M
US$ 11.440M
US$ 3.59
-0.03 -0.83
2,138
3.15M
US$ 11.310M
US$ 4.39
0.07 1.62
36,339
2.54M
US$ 11.150M
US$ 5.65
5.09 908.93
15,610
1.92M
US$ 10.850M
US$ 0.53
0.01 2.31
3.83M
20.32M
US$ 10.810M
US$ 2.20
0.07 3.19
148,503
4.91M
US$ 10.790M
US$ 1.87
0.03 1.63
79,935
5.73M
US$ 10.720M
US$ 1.47
-0.02 -1.01
515,135
7.18M
US$ 10.520M
US$ 3.71
0.41 12.42
570,565
2.82M
US$ 10.460M
US$ 0.44
-0.02 -4.61
921,157
23.48M
US$ 10.210M
US$ 0.16
0.00 0.00
0
64.53M
US$ 10.130M
C$ 0.10
0.00 0.00
0
106.10M
C$ 10.080M
US$ 7.95
-0.14 -1.73
478
1.26M
US$ 10.020M
US$ 2.92
-0.03 -1.02
157,675
3.22M
US$ 9.400M
US$ 3.01
-0.07 -2.27
268,876
3.04M
US$ 9.150M
US$ 1.63
-0.07 -4.06
58,299
5.53M
US$ 9.020M
C$ 0.17
0.00 0.00
177,400
52.95M
C$ 9.000M
US$ 16.45
-2.10 -11.32
274,779
546,667
US$ 8.990M
US$ 2.82
-0.35 -11.04
336,194
3.16M
US$ 8.910M
US$ 0.78
-0.05 -6.41
149,193
11.31M
US$ 8.830M
US$ 0.33
-0.002 -0.60
3.12M
26.07M
US$ 8.680M
US$ 0.30
-0.002 -0.67
659,489
29.01M
US$ 8.640M
US$ 2.39
-0.03 -1.24
1.02M
3.53M
US$ 8.440M
C$ 0.02
0.00 0.00
591,100
418.56M
C$ 8.370M
US$ 0.36
-0.0019 -0.53
509,984
23.14M
US$ 8.310M
US$ 1.49
-0.05 -3.25
127,344
5.56M
US$ 8.280M
US$ 1.37
0.00 0.00
0
6.03M
US$ 8.260M
US$ 0.09
0.00 0.00
0
88.99M
US$ 8.010M
US$ 0.14
0.00 0.00
0
55.37M
US$ 7.900M
US$ 4.46
0.04 0.86
76,243
1.74M
US$ 7.760M
C$ 0.03
0.00 0.00
1.23M
308.61M
C$ 7.720M
US$ 1.11
0.006 0.55
10,340
6.86M
US$ 7.590M
C$ 0.05
0.005 12.50
164,025
165.77M
C$ 7.460M
US$ 2.17
-0.06 -2.48
106,366
3.44M
US$ 7.450M
US$ 8.87
-0.24 -2.63
10,335
833,619
US$ 7.400M
US$ 12.33
-0.26 -2.07
5,020
572,658
US$ 7.060M
US$ 1.65
-0.04 -2.37
130,474
4.21M
US$ 6.950M
US$ 0.77
-0.009 -1.16
225,547
8.69M
US$ 6.690M
US$ 2.48
-0.05 -1.98
20,300
2.65M
US$ 6.570M
US$ 2.00
-0.14 -6.54
97,261
3.27M
US$ 6.540M
US$ 2.51
-0.13 -4.92
120,978
2.58M
US$ 6.480M
US$ 5.81
0.07 1.22
6,185
1.10M
US$ 6.390M
US$ 12.36
-0.46 -3.59
281,001
505,798
US$ 6.250M
US$ 4.59
0.09 2.00
29,037
1.33M
US$ 6.100M
US$ 0.13
0.00 0.00
263,551
46.48M
US$ 6.040M
US$ 0.20
0.00 0.00
0
30.12M
US$ 5.930M
US$ 1.13
-0.05 -4.24
3,600
5.17M
US$ 5.840M
US$ 0.37
-0.0012 -0.33
1.13M
15.78M
US$ 5.810M
US$ 3.53
-0.16 -4.34
7,066
1.64M
US$ 5.790M
US$ 3.46
-0.55 -13.63
116,114
1.64M
US$ 5.670M
US$ 3.68
0.02 0.46
15,043
1.54M
US$ 5.660M
US$ 0.94
0.00 0.00
0
5.97M
US$ 5.580M
US$ 2.59
-0.12 -4.43
504,267
2.13M
US$ 5.520M
US$ 1.03
0.35 51.03
119.18M
5.33M
US$ 5.490M
US$ 2.27
-0.04 -1.82
324,935
2.41M
US$ 5.470M
US$ 0.20
-0.01 -5.27
4.39M
26.19M
US$ 5.320M
US$ 0.99
-0.0038 -0.38
97,034
5.38M
US$ 5.300M
US$ 0.78
-1.24 -61.58
22.70M
6.78M
US$ 5.260M
US$ 0.70
0.01 2.03
178,550
7.44M
US$ 5.240M
US$ 0.02
0.00 0.00
0
261.79M
US$ 5.240M
US$ 8.79
-0.21 -2.34
3,930
588,167
US$ 5.170M
US$ 0.99
-0.01 -1.00
44,248
5.09M
US$ 5.040M
US$ 0.94
-0.02 -2.34
41,832
5.35M
US$ 5.030M
US$ 2.09
-0.11 -5.00
99,820
2.37M
US$ 4.950M
US$ 0.87
-0.0095 -1.09
60,738
5.46M
US$ 4.730M
US$ 3.55
-0.35 -8.90
38,827
1.32M
US$ 4.690M
US$ 0.73
0.003 0.41
170,315
6.38M
US$ 4.670M
US$ 2.06
-0.02 -0.96
288,405
2.26M
US$ 4.660M
US$ 0.88
-0.10 -10.20
1.07M
5.05M
US$ 4.440M
US$ 2.75
0.00 0.00
0
1.61M
US$ 4.430M
US$ 1.90
-0.28 -12.84
44,630
2.30M
US$ 4.370M
US$ 0.47
-0.02 -4.83
332,529
9.06M
US$ 4.290M
US$ 0.58
-0.02 -3.36
273,620
7.21M
US$ 4.150M
US$ 0.10
-0.01 -10.09
164,079
42.23M
US$ 4.140M
US$ 0.34
0.00 0.00
0
12.27M
US$ 4.130M
US$ 1.27
-0.10 -6.99
435,017
3.26M
US$ 4.120M
US$ 0.50
0.00 0.00
0
8.21M
US$ 4.110M
US$ 0.67
-0.02 -2.46
25,665
5.82M
US$ 3.920M
US$ 7.27
-0.44 -5.71
38,007
534,600
US$ 3.880M
US$ 0.89
-0.03 -3.46
51,678
4.34M
US$ 3.880M
US$ 0.22
-0.0046 -2.02
2.14M
17.23M
US$ 3.840M
US$ 0.03
0.00 0.00
0
118.11M
US$ 3.800M
US$ 0.80
0.05 6.52
465
4.47M
US$ 3.580M
US$ 0.73
-0.03 -4.54
134,245
4.80M
US$ 3.500M
US$ 0.20
0.00 0.00
0
17.21M
US$ 3.440M
US$ 0.85
-0.02 -2.30
21,523
3.79M
US$ 3.220M
US$ 2.40
0.01 0.42
50,879
1.32M
US$ 3.170M
US$ 1.24
-0.11 -7.84
1.07M
2.47M
US$ 3.050M
US$ 0.83
0.04 4.56
13.09M
3.66M
US$ 3.020M
US$ 3.44
-0.13 -3.64
162,664
868,414
US$ 2.990M
US$ 1.17
-0.02 -1.27
311,707
2.43M
US$ 2.830M
US$ 0.008
0.0003 3.90
68,500
332.76M
US$ 2.660M
US$ 0.54
-0.02 -4.37
979,457
4.87M
US$ 2.640M
US$ 0.36
0.00 0.00
0
7.24M
US$ 2.610M
US$ 1.76
-0.42 -19.12
23.19M
1.47M
US$ 2.580M
US$ 3.17
0.01 0.32
257,798
800,954
US$ 2.540M
US$ 0.56
0.00 0.00
0
4.52M
US$ 2.530M
US$ 0.25
0.00 0.00
0
9.66M
US$ 2.390M
US$ 4.57
-0.26 -5.38
475,312
521,863
US$ 2.380M
US$ 0.47
-0.01 -2.43
335,872
4.77M
US$ 2.240M
US$ 2.22
-0.02 -0.89
38,302
999,919
US$ 2.220M
US$ 0.03
0.00 0.00
500
75.46M
US$ 1.960M
US$ 0.003
0.00 0.00
0
635.88M
US$ 1.910M
US$ 0.04
0.00 0.00
0
47.10M
US$ 1.880M
C$ 0.02
0.00 0.00
0
121.27M
C$ 1.820M
C$ 0.01
0.00 0.00
259,300
177.96M
C$ 1.780M
C$ 0.07
0.00 0.00
71,000
27.30M
C$ 1.770M
US$ 0.007
-0.0004 -5.41
574,074
232.36M
US$ 1.630M
C$ 0.17
0.00 0.00
0
9.34M
C$ 1.590M
C$ 0.005
0.00 0.00
0
283.28M
C$ 1.420M
US$ 0.66
-0.02 -2.65
196,787
2.13M
US$ 1.410M
US$ 0.09
0.00 0.00
0
16.39M
US$ 1.390M
C$ 0.10
0.00 0.00
0
13.86M
C$ 1.390M
US$ 0.16
-0.01 -6.17
113,500
8.31M
US$ 1.290M
C$ 0.03
0.00 0.00
0
38.74M
C$ 1.160M
US$ 0.24
0.00 0.00
0
4.85M
US$ 1.150M
US$ 0.30
0.00 0.00
0
3.78M
US$ 1.130M
US$ 1.36
-0.05 -3.55
189,226
822,927
US$ 1.120M
US$ 0.35
-0.05 -12.50
1,001
3.18M
US$ 1.110M
US$ 0.20
0.00 0.00
0
4.44M
US$ 894K
US$ 0.03
0.00 0.00
0
29.49M
US$ 826K
US$ 0.91
0.00 0.00
0
863,788
US$ 788K
US$ 0.11
0.00 0.00
0
6.58M
US$ 705K
US$ 0.05
-0.0055 -10.68
107,739
10.98M
US$ 505K
US$ 0.36
-0.01 -2.70
13
1.24M
US$ 448K
US$ 0.25
0.00 0.00
0
1.63M
US$ 413K
US$ 0.01
-0.0001 -0.99
5.13M
39.74M
US$ 397K
US$ 0.002
0.0016 400.00
500
172.22M
US$ 344K
US$ 0.21
0.00 0.00
0
1.55M
US$ 326K
US$ 0.01
-0.0001 -0.90
3,491
26.83M
US$ 295K
US$ 0.21
0.00 0.00
0
1.39M
US$ 292K
US$ 0.07
0.00 0.00
0
4.44M
US$ 289K
US$ 0.04
-0.0035 -7.53
10,155
5.23M
US$ 225K
US$ 0.37
0.00 0.00
0
581,000
US$ 215K
US$ 0.16
0.00 0.00
0
1.33M
US$ 206K
US$ 0.003
0.0003 11.11
500
61.76M
US$ 185K
US$ 0.001
0.00 0.00
0
18.98M
US$ 19K
US$ 0.002
0.00 0.00
0
4.87M
US$ 10K
US$ 0.07
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
100.08M
US$ -
US$ 0.00
0.00 0.00
0
44.57M
US$ -
US$ 0.00
-0.0001 -100.00
205
54.52M
US$ -
US$ 1.06
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
4.70M
US$ -
US$ 0.00
0.00 0.00
0
3.14M
US$ -
US$ 3.01
0.00 0.00
0
-
US$ -
US$ 32.95
0.00 0.00
0
-
US$ -
US$ 1.20
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
125.63M
US$ -
US$ 0.00
0.00 0.00
0
42.08M
US$ -
US$ 0.00
-0.0001 -100.00
1,000
71.42M
US$ -
US$ 0.00
-0.0001 -100.00
100
112.91M
US$ -
US$ 0.00
0.00 0.00
0
5.12B
US$ -
US$ 0.00
0.00 0.00
0
514.01M
US$ -
US$ 1.81
-0.04 -2.16
184,868
-
US$ -
C$ 0.50
0.00 0.00
0
-
C$ -
US$ 5.20
-0.16 -2.99
16,022
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest Biotechnology Stock News


Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2025 after market close on Tuesday, August 5, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific... Read more


Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 360,550 shares of its common stock to 60 employees pursuant to the Company’s... Read more


Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern’s AI platform, RADR ®, and will initially focus on tailored combinations of DNA damaging agents and DNA repair inhibitors Addresses $50+ billion combination cancer therapy market projected to grow 8.5% annually through 2030 Over 60% of cancer patients received DNA damaging agents or DNA repair inhibitors as part of their clinical treatment and unique AI-powered module will focus... Read more


Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

EB-003 significantly decreased context-induced freezing behavior one-hour post-dose (p < 0.05) indicating a positive therapeutic effect in well-established translational rodent model for PTSD CAMBRIDGE, Mass. / Jul 15, 2025 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological... Read more


Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™ CRANFORD, N.J., July 15, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the execution of a distribution services agreement with Cencora (formerly AmerisourceBergen), a global pharmaceutical... Read more


Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control...

Approximately 95% of adult and pediatric patients were exposed to supraphysiologic doses of glucocorticoids and/or experienced elevated androstenedione levels at least once during their treatment journey Real-world findings underscore long-term challenges of managing classic congenital adrenal hyperplasia and highlight clinical need for therapies to reduce androgen excess without high glucocorticoid doses SAN DIEGO, July 15, 2025 /PRNewswire/ -- Neurocrine Biosciences,... Read more


MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

iNKT cells uniquely remodel the tumor microenvironment, overcome immune resistance, and enable scalable off-the-shelf cell therapy NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies, today announced the publication of a peer-reviewed article titled “CAR-iNKT Cells: Redefining the Frontiers of Cellular Immunotherapy”... Read more


Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

LOS ANGELES / Jul 15, 2025 / Business Wire / Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim safety analysis of the trial demonstrated that ENV-105, a first-in-class CD105 antagonist, was well tolerated when... Read more


Clearmind Medicine Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled

Vancouver, Canada, July 15, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the expansion of its Phase I/IIa clinical trial for CMND-100, its proprietary MEAI-based oral treatment candidate for Alcohol Use Disorder (AUD), with the activation... Read more


Perre Fabre Pharmaceuticals Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics

Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical program Enrollment is ongoing for pivotal, Phase 3 ALLELE Study (NCT03394365) investigating tabelecleucel in patients with EBV+PTLD in Solid Organ Transplant and Allogeneic Hematopoietic Cell Transplant after failure of standard therapy NCT04554914 also open for enrollment to patients with EBV-associated diseases Atara Biotherapeutics resubmitted the... Read more


Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide

Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extension This patent covers novel cyclic peptides and their use in treating solid tumors BASKING RIDGE, N.J, July 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases,... Read more


Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor, today announced the signing of a new commercial agreement with a non-disclosed EU-based biotechnology company. The agreement provides the partner with a non-exclusive global license to a range of selected proprietary... Read more


PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of weekly injections. The GLP-1 delivery platform expands PolyPid's product portfolio beyond the recently successful Phase 3 D-PLEX100, demonstrating versatility of the Company's proprietary drug delivery platforms in multiple major therapeutic areas. PETACH TIKVA, Israel, July... Read more


Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Dr. Lotan’s distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada’s NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced... Read more


SELLAS Life Sciences Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study

The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg Twice a Week (BIW) and 50% in AML MR with Myelomonocytic/Myelomonoblastic (M4/M5) Subtype Median Overall Survival (mOS) of 8.9 Months in Patients with AML MR and 8.8 mOS in Relapsed or Refractory to Venetoclax-Based Regimens at 30 mg BIW Dose Level Surpasses the Historical... Read more


Palatin Technologies Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity

Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment Combination of oral PL7737 and tirzepatide resulted in additive weight loss effects IND-enabling toxicology program ongoing IND submission planned for 4Q2025; Clinical data expected in 1H2026 PRINCETON, N.J., July 15, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that... Read more


ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetes FDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for both accelerated approval and for full approval Nearly half of the patients required for the accelerated approval analysis using eGFR slope have been enrolled Topline data to support an application for accelerated approval is anticipated in Q2 20... Read more


Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining Your Approach to Leptomeningeal Metastases” HOUSTON, July 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous... Read more


Abeona Therapeutics: ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Lucile Packard Children’s Hospital Stanford is ready to accept patients for ZEVASKYN treatment Abeona Therapeutics® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) approval of ZEVASKYN in April 2025 ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application CLEVELAND, July 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today... Read more


BriaCell Therapeutics Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the addition of a key clinical site, Mayo Clinic, to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as NCT06072612) in metastatic breast cancer. BriaCell’s... Read more


Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection

MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio's ultrasensitive immunoassays for challenging low-abundance biomarkers, including key Alzheimer's disease biomarkers such as phosphorylated tau 217 (pTau 217),... Read more


60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

New Drug Application intended for 2026, subject to generation of positive data from three U.S. clinical trials planned or in progress Total addressable market (TAM) for ARAKODA for Human Babesiosis is informed by results of a 6,000 nationwide patient survey and a quantitative research study involving 300 healthcare professionals WASHINGTON, July 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”),... Read more


Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen Company expects to begin enrolling patients in Phase 2 in 2H 2025 SAN DIEGO and SUZHOU, China, July 15, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced outcomes from its Type B... Read more


Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

Acumen and JCR aim to develop a product leveraging Acumen’s amyloid beta oligomer-selective antibody expertise and JCR’s transferrin-receptor-targeting blood-brain barrier-penetrating technology Preclinical candidate data expected in early 2026, with exclusive option for Acumen to develop up to two development candidates for the treatment of Alzheimer’s disease Agreement follows more than one year of engagement to assess technical feasibility and profile series... Read more


Apellis Pharmaceuticals Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held July 30 - August 2 in Long Beach, California. These data further demonstrate the robust efficacy and well-documented safety profile of SYFOVRE® (pegcetacoplan injection) for patients with geographic atrophy (GA) secondary... Read more


Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025 Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that Health... Read more


Kane Biotech to Present at Advanced Wound Care Summit USA

WINNIPEG, Manitoba, July 14, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) announces today that Kane Biotech’s Interim Chief Executive Officer, Dr. Robert Huizinga, will be presenting at the 4th Advanced Wound Care Summit USA taking place from July 15-17, 2025 in Boston, MA. The Advanced Wound Care Summit USA is an industry gathering dedicated to the business of wound care where innovators, payers, regulators, and multinational... Read more


Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeti

Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductions Substantial improvements in insulin resistance were also observed in both adult and pediatric patients treated with CRENESSITY compared with placebo through one year of treatment SAN DIEGO, July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data... Read more


Longevity Health Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction

PITTSBURGH, July 14, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on human longevity and healthy aging (“Longevity”, the “Company”, “we”, “our”, or “us”), today announced the execution of a definitive merger agreement (the “Merger”) with True Health Inc., a leading player in the fast growing plasma collection industry under the THPlasma brand (“THPlasma”), to combine the companies in an all-stock... Read more


Ascendis Pharma: New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney...

COPENHAGEN, Denmark, July 14, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism regardless of its cause (post-surgical, autoimmune, genetic, or idiopathic), including improvements in biochemistries, kidney function, and quality of life. Results were... Read more


60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

Data from three independent clinical studies demonstrate utility of tafenoquine to treat acute canine babesiosis WASHINGTON, July 14, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that the Company will conduct a gap analysis of its existing data prior to submitting a Minor Use Minor Species... Read more


Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

Both Tru Niagen, featured as the newest in-room offering for hotel guests, and Niagen IV, available at NutriDrip’s location at The Spa by Equinox Hotel New York, support cellular energy production and DNA repair for optimal recovery LOS ANGELES / Jul 14, 2025 / Business Wire / Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced... Read more


Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025

One-year data from CAHtalyst™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia Results build upon previously reported one-year data from CAHtalyst™ Pediatric study SAN DIEGO, July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new one-year data from the CAHtalyst™ Adult study... Read more


Disc Medicine Appoints Nadim Ahmed to its Board of Directors

WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics. “I am excited to welcome Nadim to Disc’s... Read more


Biodexa Pharmaceuticals Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced the filing of a Clinical Trial Application (CTA) with the European Medicines Agency (EMA) for its Serenta trial in patients... Read more


Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Atara Biotherapeutics Resubmits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease to the U.S. FDA Approval of BLA Would Trigger $40 Million Milestone Payment from Pierre Fabre Laboratories THOUSAND OAKS, Calif. / Jul 14, 2025 / Business Wire / Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV)... Read more


Corcept Therapeutics Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif. / Jul 14, 2025 / Business Wire / Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary, selective cortisol modulator, relacorilant, to treat... Read more


ESSA Pharma Announces Definitive Agreement to be Acquired by XenoTherapeutics Backed by XOMA Royalty Corporation in All-Cash Transaction

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif., July 14, 2025 /CNW/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that it has entered into a definitive agreement (the "Business Combination Agreement") with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the "Transaction") all of the issued and outstanding common shares of ESSA (the "Common Shares"). XOMA... Read more


Daré Bioscience: Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Interim Phase 3 Results Support Ovaprene’s Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive SAN DIEGO, July 14, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial evaluating the contraceptive effectiveness,... Read more


Ultragenyx Pharmaceutical: Health Canada Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

First and only medicine approved by Health Canada for patients as young as 6-months of age with HoFH, an ultrarare, inherited form of high cholesterol TORONTO, July 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, today announced that Health Canada has extended the approval of Evkeeza® (evinacumab) as... Read more


Avalon GloboCare Announces Patent Issuance for Novel CAR-T and CAR-NK Cell Technology in Hong Kong

FREEHOLD, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced the issuance of a new standard patent by the Hong Kong Intellectual Property Department (HKIPD) for its proprietary CAR-T and CAR-Natural Killer (NK) cell technology. Granted based on a Chinese patent (ZL202080015205.0) and issued as Patent No. HK40074322, the Certificate of Invention... Read more


OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

Cash runway extended through 2026, beyond September 30, 2026 sunset date for rare pediatric priority review voucher (PRV) program Additional funding allows Company to advance strategic alternatives for OS Animal Health, close out OST-504 (previously ADXS-504) prostate cancer study and initiate AI-driven next-gen tADC product candidate modeling New York, New York--(Newsfile Corp. - July 14, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"),... Read more


Iovance Biotherapeutics: Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

61% Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that a real-world, retrospective study demonstrates the benefit of commercial Amtagvi® (lifileucel) in real-world clinical... Read more


Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

MINNEAPOLIS, July 14, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the issuance of U.S. Patent No. 12,350,276 covering the clinical dosing regimen for its lead drug candidate, gedatolisib, in ER+/HER2- breast cancer patients. The patent extends Celcuity’s patent exclusivity in the U.S. into 2042. “This dosing regimen patent reflects our commitment... Read more


Collplant Biotechnologies Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations

New U.S.-based role to support growth strategy, partnerships, and scaling of rhCollagen product platforms REHOVOT, Israel, July 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced the appointment of Bowman Bagley as Vice President, Commercial North America. In this newly... Read more


Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

MINNEAPOLIS, July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics® (NASDAQ: ABEO). Throughout clinical development, Simple Western enabled precise identification and... Read more


I-Mab to Present at the BTIG Virtual Biotechnology Conference

ROCKVILLE, Md., July 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-30, 2025. Conference details are as follows: BTIG Virtual Biotechnology ConferenceFormat: Fireside Chat and one-on-one... Read more


Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides

SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that the design of the adaptive clinical trial protocol for the treatment of MPox Virus Clade Ia and Ib infections and disease is nearly complete. The adaptive clinical... Read more


Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to S...

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA. Details of the presentations are as follows: Abstract Title:... Read more


Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer

Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that its highly impactful programs on ADC and Radiopharma programs, which includes collaborations and preclinical studies on cancer therapies with Accum® are ongoing. Defence's Accum®-based ADCs have demonstrated enhanced... Read more